In a patient with ILD and metastatic NSCLC with positive PD-L1, would you give chemo/pembrolizumab, chemotherapy alone, or pembrolizumab alone?
Does the degree of PD-L1 expression weigh into your decision?
Community PollStarted
How do you treat a patient with ILD and metastatic NSCLC with PD-L1 > 50%?
45 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Indiana University School of Medicine
Answered on
We always discuss the risks and benefits of treatment to every patient; however, patients still rely upon our best judgment to guide decisions. I would not recommend a PD-1 or PD-L1 inhibitor to a patient with known interstitial lung disease. These patients were excluded from the Keynote, Checkmate,...
Join for free or sign in to see the full answer